Company Overview of Twinstrand Therapeutics, Inc.
As of July 7, 2009, Twinstrand Therapeutics, Inc. was acquired by Cangene Corp. Twinstrand Therapeutics, Inc. operates as a biopharmaceutical company which engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. Its products include TST10088, a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. The company was formerly known as De Novo Enzyme Corporation and changed its name to Twinstrand Therapeutics, Inc. in January 2000. The company was founded in 1995 and is based in North Vancouver, Canada.
267 West Esplanade
North Vancouver, BC V7M 1A5
Founded in 1995
Key Executives for Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Hemax Genome, Inc.||Americas|
|Trudell Medical International||Americas|
|SynX Pharma Inc.||Americas|
|Indel Therapeutics Inc||Americas|
|SMC Ventures Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Twinstrand Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.